4.2 Article

The effects of sulforaphane on canine osteosarcoma proliferation and invasion

期刊

VETERINARY AND COMPARATIVE ONCOLOGY
卷 15, 期 3, 页码 718-730

出版社

WILEY
DOI: 10.1111/vco.12212

关键词

sulforaphane; osteosarcoma; apoptosis; focal adhesion kinase; antioxidant

向作者/读者索取更多资源

Recent evidence in in vitro and in vivo models suggests that sulforaphane (SFN), found in raw cruciferous vegetables, may have utility in chemoprevention, as an antineoplastic agent and as a free radical scavenger. The effects of SFN alone or with doxorubicin on cell viability were examined, as well as cell cycle kinetics, invasion capabilities and apoptosis in three canine osteosarcoma cell line (D17, OS 2.4 and HMPOS). Results showed that SFN could not induce cell death at potentially physiological concentrations (< 50 mu M), but significantly diminished cell invasion and downregulation of focal adhesion kinase (FAK) signaling. Modest cell cycle changes were observed in each cell line. When doxorubicin was used in conjunction with SFN, there was a protective effect to doxorubicin-induced cytotoxicity in D17 and OS 2.4 cells. Further studies examining SFN as a supplement are warranted, particularly in light of pro-proliferative and cytoprotective properties in canine osteosarcoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Evaluation of canonical Hedgehog signaling pathway inhibition in canine osteosarcoma

Vincent E. Baldanza, Anita Rogic, Weiwei Yan, Corri B. Levine, Roy A. Levine, Andrew D. Miller, Angela L. McCleary-Wheeler

PLOS ONE (2020)

Article Immunology

Establishment of an African green monkey model for COVID-19 and protection against re-infection

Courtney Woolsey, Viktoriya Borisevich, Abhishek N. Prasad, Krystle N. Agans, Daniel J. Deer, Natalie S. Dobias, John C. Heymann, Stephanie L. Foster, Corri B. Levine, Liana Medina, Kevin Melody, Joan B. Geisbert, Karla A. Fenton, Thomas W. Geisbert, Robert W. Cross

Summary: African green monkeys infected with SARS-CoV-2 exhibit symptoms closely resembling those in humans, making them a valuable model for studying COVID-19 pathogenesis and testing medical interventions.

NATURE IMMUNOLOGY (2021)

Article Virology

Comparison of Zaire and Bundibugyo Ebolavirus Polymerase Complexes and Susceptibility to Antivirals through a Newly Developed Bundibugyo Minigenome System

Corri B. Levine, Chad E. Mire, Thomas W. Geisbert

Summary: This study presents a mini-genome replication system for studying transcription of BDBV as compared to EBOV and evaluating small molecule inhibitors. The research highlights the impact of protein interactions within the polymerase complexes on genome transcription efficiency, particularly the influence of the nucleoprotein and the 3'-untranslated region. The findings suggest intrinsic specificities in the polymerase complexes and untranslated signaling regions that may provide insight into pathogenic differences.

JOURNAL OF VIROLOGY (2021)

Article Biochemistry & Molecular Biology

Synthetic proteins for COVID-19 diagnostics

Catherine H. Schein, Corri B. Levine, Susan L. F. McLellan, Surendra S. Negi, Werner Braun, Stephen C. Dreskin, Elizabeth S. Anaya, Jurgen Schmidt

Summary: A small, synthetic protein JS7 has been identified as a potential basis for specific diagnostics for SARS-CoV-2 infections, with associations found in sera from COVID-19 patients. By analyzing the binding between various antibodies and JS7, assessments can be made based on disease severity and clinical outcomes.

PEPTIDES (2021)

Article Critical Care Medicine

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial

Andre C. Kalil, Aneesh K. Mehta, Thomas F. Patterson, Nathaniel Erdmann, Carlos A. Gomez, Mamta K. Jain, Cameron R. Wolfe, Guillermo M. Ruiz-Palacios, Susan Kline, Justino Regalado Pineda, Anne F. Luetkemeyer, Michelle S. Harkins, Patrick E. H. Jackson, Nicole M. Iovine, Victor F. Tapson, Myoung-don Oh, Jennifer A. Whitaker, Richard A. Mularski, Catharine Paules, Dilek Ince, Jin Takasaki, Daniel A. Sweeney, Uriel Sandkovsky, David L. Wyles, Elizabeth Hohmann, Kevin A. Grimes, Robert Grossberg, Maryrose Laguio-Vila, Allison A. Lambert, Diego Lopez de Castilla, EuSuk Kim, LuAnn Larson, Claire R. Wan, Jessica J. Traenkner, Philip O. Ponce, Jan E. Patterson, Paul A. Goepfert, Theresa A. Sofarelli, Satish Mocherla, Emily R. Ko, Alfredo Ponce de Leon, Sarah B. Doernberg, Robert L. Atmar, Ryan C. Maves, Fernando Dangond, Jennifer Ferreira, Michelle Green, Mat Makowski, Tyler Bonnett, Tatiana Beresnev, Varduhi Ghazaryan, Walla Dempsey, Seema U. Nayak, Lori Dodd, Kay M. Tomashek, John H. Beigel

Summary: This study compared the efficacy of interferon beta-1a in combination with remdesivir versus remdesivir alone in hospitalised COVID-19 patients. The results showed no significant difference in time to recovery and mortality rate between the interferon beta-1a plus remdesivir group and the placebo plus remdesivir group, with patients requiring high-flow oxygen at baseline having poorer outcomes after interferon beta-1a treatment.

LANCET RESPIRATORY MEDICINE (2021)

Review Infectious Diseases

Lassa Virus Infection: a Summary for Clinicians

Vanessa Raabe, Aneesh K. Mehta, Jared D. Evans, Adam Beitscher, Nahid Bhadelia, David Brett-Major, Theodore J. Cieslak, Richard T. Davey, Jared D. Evans, Maria G. Frank, Peter Iwen, Mark G. Kortepeter, Corri Levine, Susan McLellan, Aneesh K. Mehta, Lauren Sauer, Erica S. Shenoy, Kimon Zachary

Summary: This article provides a concise overview of Lassa virus infection and Lassa fever disease from a clinical perspective. It summarizes the pathogenesis, clinical features, diagnostics, and potential therapies and vaccines for clinical or research use. The review highlights the current status of antiviral medications, vaccines, and treatment options, emphasizing the need for further research and clinical trials. This resource serves as a rapid reference for clinicians facing suspected infections.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

Article Critical Care Medicine

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Cameron R. Wolfe, Kay M. Tomashek, Thomas F. Patterson, Carlos A. Gomez, Vincent C. Marconi, Mamta K. Jain, Otto O. Yang, Catharine Paules, Guillermo M. Ruiz Palacios, Robert Grossberg, Michelle S. Harkins, Richard A. Mularski, Nathaniel Erdmann, Uriel Sandkovsky, Eyad Almasri, Justino Regalado Pineda, Alexandra W. Dretler, Diego Lopez de Castilla, Angela R. Branche, Pauline K. Park, Aneesh K. Mehta, William R. Short, Susan L. F. McLellan, Susan Kline, Nicole M. Iovine, Hana M. El Sahly, Sarah B. Doernberg, Myoung-don Oh, Nikhil Huprikar, Elizabeth Hohmann, Colleen F. Kelley, Mark Holodniy, Eu Suk Kim, Daniel A. Sweeney, Robert W. Finberg, Kevin A. Grimes, Ryan C. Maves, Emily R. Ko, John J. Engemann, Barbara S. Taylor, Philip O. Ponce, LuAnn Larson, Dante Paolo Melendez, Allan M. Seibert, Nadine G. Rouphael, Joslyn Strebe, Jesse L. Clark, Kathleen G. Julian, Alfredo Ponce de Leon, Anabela Cardoso, Stephanie de Bono, Robert L. Atmar, Anuradha Ganesan, Jennifer L. Ferreira, Michelle Green, Mat Makowski, Tyler Bonnett, Tatiana Beresnev, Varduhi Ghazaryan, Walla Dempsey, Seema U. Nayak, Lori E. Dodd, John H. Beigel, Andre C. Kalil

Summary: In hospitalized patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse events.

LANCET RESPIRATORY MEDICINE (2022)

Article Immunology

Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2

Jonathan Fintzi, Tyler Bonnett, Pablo Tebas, Vincent C. Marconi, Corri B. Levine, Hana M. El Sahly, Susan L. F. McLellan, Constance A. Benson, Christina A. Rostad, Anuradha Ganesan, Nikhil Huprikar, Maria G. Frank, Richard A. Mularski, Robert L. Atmar, Pauline K. Park, William R. Short, John H. Beigel, Aneesh K. Mehta, Daniel A. Sweeney

Summary: The study showed that the combination therapy of baricitinib and remdesivir sped recovery in COVID-19 patients, particularly those requiring high levels of respiratory support, compared to remdesivir monotherapy.

OPEN FORUM INFECTIOUS DISEASES (2022)

Article Public, Environmental & Occupational Health

Prepared to Act: Lessons Learned by the Special Pathogens Research Network, Based on Collaborations with the NIAID-Led Adaptive COVID-19 Treatment Trial

Corri B. Levine, Sami Vasistha, Caroline Croyle Persson, LuAnn R. Larson, Christopher J. Kratochvil, Aneesh K. Mehta, Lindsay J. Hicks, Abigail E. Lowe, Mark G. Kortepeter, Lauren M. Sauer

Summary: Well-controlled clinical trials are essential for advancing medicine, even during emergency medical events like infectious disease outbreaks. The Special Pathogens Research Network played a crucial role in the Adaptive COVID-19 Treatment Trial and provided valuable feedback and recommendations for conducting future studies during pandemics.

HEALTH SECURITY (2022)

Article Public, Environmental & Occupational Health

Contributions of the Regional Emerging Special Pathogen Treatment Centers to the US COVID-19 Pandemic Response

Jonathan D. Grein, Jennifer A. Garland, Christa Arguinchona, Maria G. Frank, Brian T. Garibaldi, Amanda Grindle, Angela Hewlett, Susan Kline, Corri B. Levine, Aneesh Mehta, Vikramjit Mukherjee, Lauren M. Sauer, Eileen F. Searle, Sharon Vanairsdale, Angela Vasa

Summary: The National Emerging Special Pathogens Training and Education Center (NETEC) and the Regional Emerging Special Pathogen Treatment Centers (RESPTCs) network played a pivotal role in the US COVID-19 pandemic response by providing essential support, isolation capacity, and expertise to strengthen the national healthcare system's readiness.

HEALTH SECURITY (2022)

Article Virology

Vaccination Decreases the Infectious Viral Load of Delta Variant SARS-CoV-2 in Asymptomatic Patients

Jessica A. Plante, Rafael R. G. Machado, Brooke M. Mitchell, Divya P. Shinde, Jordyn Walker, Dionna Scharton, Allan McConnell, Nehad Saada, Jianying Liu, Bilal Khan, Rafael K. Campos, Bryan A. Johnson, Vineet D. Menachery, Corri B. Levine, Ping Ren, Susan L. F. McLellan, Kenneth S. Plante, Scott C. Weaver

Summary: The Delta variant of SARS-CoV-2 can cause breakthrough infections in fully vaccinated individuals. Vaccination reduces the infectious viral load and increases the levels of anti-spike IgA in the nasal secretions of asymptomatic individuals infected with the Delta variant.

VIRUSES-BASEL (2022)

Article Medicine, General & Internal

Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial

Gail E. Potter, Tyler Bonnett, Kevin Rubenstein, David A. Lindholm, Rekha R. Rapaka, Sarah B. Doernberg, David C. Lye, Richard A. Mularski, Noreen A. Hynes, Susan Kline, Catharine Paules, Cameron R. Wolfe, Maria G. Frank, Nadine G. Rouphael, Gregory A. Deye, Daniel A. Sweeney, Rhonda E. Colombo, Richard T. Davey, Aneesh K. Mehta, Jennifer A. Whitaker, Jose G. Castro, Alpesh N. Amin, Christopher J. Colombo, Corri B. Levine, Mamta K. Jain, Ryan C. Maves, Vincent C. Marconi, Robert Grossberg, Sameh Hozayen, Timothy H. Burgess, Robert L. Atmar, Anuradha Ganesan, Carlos A. Gomez, Constance A. Benson, Diego Lopez de Castilla, Neera Ahuja, Sarah L. George, Seema U. Nayak, Stuart H. Cohen, Tahaniyat Lalani, William R. Short, Nathaniel Erdmann, Kay M. Tomashek, Pablo Tebas

Summary: This study evaluated the impact of evolving COVID-19 standard of care (SOC) on patient recovery and mortality using data from ACTT. The results suggest that changes in SOC were associated with improved outcomes, but not all improvements could be attributed to SOC changes. These findings are important for the analysis of platform trials in rapidly changing therapeutic areas by excluding nonconcurrent controls.

ANNALS OF INTERNAL MEDICINE (2022)

Article Immunology

Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case

Ana M. Ortega-Villa, Noreen A. Hynes, Corri B. Levine, Katherine Yang, Zanthia Wiley, Nikolaus Jilg, Jing Wang, Jennifer A. Whitaker, Christopher J. Colombo, Seema U. Nayak, Hannah Jang Kim, Nicole M. Iovine, Dilek Ince, Stuart H. Cohen, Adam J. Langer, Jonathan M. Wortham, Robert L. Atmar, Hana M. El Sahly, Mamta K. Jain, Aneesh K. Mehta, Cameron R. Wolfe, Carlos A. Gomez, Tatiana Beresnev, Richard A. Mularski, Catharine Paules, Andre C. Kalil, Angela R. Branche, Annie Luetkemeyer, Barry S. Zingman, Jocelyn Voell, Michael Whitaker, Michelle S. Harkins, Richard T. Davey, Robert Grossberg, Sarah L. George, Victor Tapson, William R. Short, Varduhi Ghazaryan, Constance A. Benson, Lori E. Dodd, Daniel A. Sweeney, Kay M. Tomashek

Summary: This study evaluates the utility of COVID-NET, CCSS, and US Census data to determine demographic representation in the ACTT trial. The study finds that ACTT enrolled a similar or higher proportion of Hispanic/Latino and White participants compared to COVID-NET and a higher proportion compared to US Census and CCSS. The proportion of participants aged ≥65 years was similar or lower than COVID-NET and higher than CCSS and the US Census. The proportion of females enrolled in ACTT was lower than in the reference datasets.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Biochemistry & Molecular Biology

Hydrogen Sulfide Ameliorates SARS-CoV-2-Associated Lung Endothelial Barrier Disruption

Olivier Escaffre, Peter Szaniszlo, Gabor Toro, Caitlyn L. L. Vilas, Brenna J. J. Servantes, Ernesto Lopez, Terry L. L. Juelich, Corri B. B. Levine, Susan L. F. McLellan, Jessica C. C. Cardenas, Alexander N. N. Freiberg, Katalin Modis

Summary: Recent studies have found that lung microvascular endothelial injury plays a crucial role in the development of COVID-19. This study explored the effects of H2S on the barrier function of lung endothelial cells and its potential therapeutic implications for COVID-19. The researchers observed that treatment with GYY4137, a slow-releasing H2S donor, reduced endothelial barrier permeability after exposure to plasma samples from COVID-19 patients or inactivated SARS-CoV-2 virus. These findings suggest that H2S-releasing compounds have the potential to ameliorate lung endothelial barrier disruption caused by SARS-CoV-2.

BIOMEDICINES (2023)

暂无数据